-
2025 North-South Summit | Dr. Man Li: Treatment Optimization and Strategic Advancements for HR+/HER2- Breast Cancer Patients
Oncology Frontier: CDK4/6 inhibitors have shown significant efficacy in the treatment of HR+/HER2- advanced breast cancer. How do you view the role of CDK4/6 inhibitors in future treatment strategies? Are…
-
Academician Binghe Xu: Clinical Research Advances in Breast Cancer in China and the Outlook for the SGBCC Conference
Oncology Frontier: At this conference, you gave a lecture titled “Advances and Outlook of Breast Cancer Drug Clinical Research in China.” Could you summarize your lecture and share the key…
-
ASCO GU 2025 | Dr. Philip Kwong: Precision Testing and Individualized Management in mCRPC
The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was held in San Francisco, California, from February 13 to 15. It attracted top experts and scholars in the field of urology from around the world. At this conference, Oncology Frontier invited Dr. Philip Kwong from The University of Hong Kong to share…
-
Dr. Angela Jia: Rapid Development of Radioligand Therapy, Combined with Local Radiotherapy May Further Improve Survival in Prostate Cancer Patients
Radioligand Therapy (RLT) is an innovative treatment modality in the field of prostate cancer, enriching the therapeutic options. With further research, the personalized application of RLT and its combination with other therapies will become an important direction for the future treatment of prostate cancer. Oncology Frontier invited Dr. Angela Jia, an expert in radiation oncology…
-
Dr. Taiyuan Li: NOSES Surgery – From “Minimally Invasive” to “Scarless” at the Chinese Medical Doctor Association’s Colorectal Oncology Committee
The Rise of NOSES Surgery: From Concept to Clinical Transformation NOSES (Natural Orifice Specimen Extraction Surgery) was first proposed as a surgical concept by Professor Xishan Wang in China. After…
-
Dr. Guiyu Wang: Surgical Updates & Future of Minimally Invasive Treatment | CMDA Colorectal Oncology Annual Meeting
CME Surgery: The Standard Choice for High-Volume Centers Radical surgery remains the cornerstone of colorectal cancer treatment, requiring both complete tumor resection with regional lymph node dissection and the preservation…
-
Dr. Guanghai Dai: MDT’s Role in Colorectal Cancer Treatment | Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee
MDT Evolution: From Exploration to Precision Oncology Multidisciplinary Team (MDT) treatment is a clinical model in which a fixed team of experts from multiple disciplines collaborates regularly to discuss specific…
-
Dr. Wei Zhang: Two Decades of Organ-Preserving Surgery for Low Rectal Cancer in China – Reflections and Future Directions| Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee
At the 9th Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee, Dr. Wei Zhang from The First Affiliated Hospital of the Naval Medical University reviewed the 20-year progress in the treatment of low rectal cancer in China and outlined future directions in the field. His presentation highlighted major advancements in organ-preserving surgery,…
Connecting Medical Expertise through Media